-

GlycoMimetics to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that management will participate in two upcoming investor conferences.

The Stifel 2022 Healthcare Conference on November 15, 2022 – management will attend and host 1x1 investor meetings.

The Jefferies London Healthcare Conference on November 17, 2022 at 10:50 a.m. EST – management will participate in an in-person fireside chat.

An archived recording of the Jefferies fireside chat will be available for 90 days on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations.

About GlycoMimetics, Inc.

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company’s science is based on understanding the role that carbohydrates play on the surface of every living cell and applying specialized chemistry to discover small molecule drugs, known as glycomimetics, that alter these carbohydrate-mediated pathways in diverse disease states, including cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly-owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is in Rockville, MD in the BioHealth Capital Region. Learn more atwww.glycomimetics.com.

Contacts

Investors:
Argot Partners
Leo Vartorella / Carrie McKim
212-600-1902
Glycomimetics@argotpartners.com

Industry:

GlycoMimetics, Inc.

NASDAQ:GLYC
Release Versions
English

Contacts

Investors:
Argot Partners
Leo Vartorella / Carrie McKim
212-600-1902
Glycomimetics@argotpartners.com

More News From GlycoMimetics, Inc.

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, Inc. (“Crescent”), along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics’ special meeting in lieu of the annual meeting of stockholders held on June 5, 2025 (the “Special Meeting”), including a reverse stock split of GlycoMimetics’ common stock to be effected...

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024. ASH Annual Meeting abstracts may be accessed online at www.hematology.org. Details of GlycoMimetics presentations are as follows (...

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc. (“Crescent”), a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the Company plans to operate under the name Crescent Biopharma, Inc. In support of the acquisition, a syndicate of investors led by Fairmount, Venrock Healthcare Capital Par...
Back to Newsroom